Peritoneal Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Clinical Trials

A Phase II Study of Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Condition:   PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment Intervention:   Drug: Orevogomab+PLD Sponsor:   Yonsei University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2022 Category: Research Source Type: clinical trials